Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Jul 2021
FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer
10 July 2021 - On 9 July 2021, the FDA approved enfortumab vedotin-ejfv (Padcev), for adult patients with locally advanced ...
Posted by Michael Wonder on 09 Jul 2021
ICER publishes evidence report on therapies for atopic dermatitis
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...
Posted by Michael Wonder on 09 Jul 2021
Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis
9 July 2021 - EMA’s safety committee (PRAC) has concluded that myocarditis and pericarditis can occur in very rare cases ...
Posted by Michael Wonder on 09 Jul 2021
Pfizer plans to request FDA approval for COVID booster shot in August
9 Jul 2021 - Pfizer plans to request US emergency authorisation in August for a third booster dose of its ...
Posted by Michael Wonder on 08 Jul 2021
BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in oesophageal squamous cell carcinoma
7 July 2021 - BeiGene today announced that the Center for Drug Evaluation of the China National Medical Products Administration ...
Posted by Michael Wonder on 08 Jul 2021
Y-mAbs announces NMPA submission of BLA for Danyelza (naxitamab-gqgk) in China
6 July 2021 - Y-mAbs Therapeutics today announced that SciClone Pharmaceuticals has submitted the biologics license application for Danyelza (naxitamab-gqgk) for ...
Posted by Michael Wonder on 08 Jul 2021
ATAGI update following weekly COVID-19 meeting – 7 July 2021
8 July 2021 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 7 July ...
Posted by Michael Wonder on 08 Jul 2021
House report: drug companies spent more on buybacks, dividends than research
8 July 2021 - House Democrats on Thursday released a report that found that the 14 leading drug companies paid ...
Posted by Michael Wonder on 08 Jul 2021
Lysogene announces FDA fast track designation for LYS-GM101 gene therapy for the treatment of GM1 gangliosidosis
8 July 2021 - Lysogene today announced that the U.S. FDA has granted fast track designation to its LYS-GM101 program, which ...
Posted by Michael Wonder on 08 Jul 2021
In a reversal, FDA calls for limits on who gets Alzheimer’s drug
8 July 2021 - The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the ...
Posted by Michael Wonder on 08 Jul 2021
COVID-19: flood of Pfizer doses finally here
8 July 2021 - Australia has clinched a potentially game-changing deal to triple its access to Pfizer Covid-19 vaccines to one ...
Posted by Michael Wonder on 08 Jul 2021
FDA approves updated Aduhelm prescribing information to emphasise population studied in clinical trials
8 July 2021 - Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s ...
Posted by Michael Wonder on 08 Jul 2021
Tezepelumab regulatory submission accepted and granted FDA priority review in the US for the treatment of patients with asthma
8 July 2021 - Tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a ...
Posted by Michael Wonder on 08 Jul 2021
COVID-19 vaccine weekly safety report (8 July 2021)
8 July 2021 - Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia ...
Posted by Michael Wonder on 08 Jul 2021
Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia
7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...